DDInter948 DDInter223
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.
Bosentan {u} (Compound) binds {v} (Gene) EDNRA
Bosentan {u} (Compound) downregulates {v} (Gene) PSMB8
Bosentan {u} (Compound) causes {v} (Side Effect) Hepatobiliary disease
Bosentan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Bosentan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Bosentan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dronabinol
Bosentan {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Bosentan (Compound) binds EDNRA (Gene)
Bosentan (Compound) downregulates PSMB8 (Gene)
Bosentan (Compound) causes Hepatobiliary disease (Side Effect)
Bosentan may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol
Bosentan may lead to a major life threatening interaction when taken with Encorafenib